SCHEMBL1337828

SCHEMBL1337828

CCOc1cccc(-c2cc(F)c(N)c(Cl)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAP4K4 O95819 1/20 0.46
NOTUM Q6P988 1/20 0.46
DHODH Q02127 6/20 0.45
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
PTGS2 P35354 1/20 0.44
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FFAR1 O14842 1/20 0.41
PPARD Q03181 1/20 0.41
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
NR3C1 P04150 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337634 0.90 TP53 (0.54) TP53CYP3A4MAP4K4NOTUMDHODH
SCHEMBL1335616 0.90 TP53 (0.54) TP53CYP3A4MAP4K4NOTUMRXRA
SCHEMBL1337914 0.89 KDM4E (0.48) DHODHKDM4EGAAMAPTMEN1
SCHEMBL29709289 0.88 SMN1; SMN2 (0.49) DHODHKDM4EMEN1KMT2A
SCHEMBL1337329 0.88 SMN1; SMN2 (0.49) DHODHKDM4EMEN1KMT2A
SCHEMBL1336932 0.85 NR4A2 (0.44) CYP3A4DHODHPTGS2MEN1KMT2A
SCHEMBL1335619 0.84 ALDH1A1 (0.40) MAPTMEN1KMT2A
SCHEMBL1336962 0.80 MAP4K4 (0.53) TP53CYP3A4MAP4K4NOTUMDHODH
SCHEMBL3732621 0.80 MAP4K4 (0.53) TP53CYP3A4MAP4K4NOTUMRXRA
SCHEMBL1335751 0.79 DHODH (0.44) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR TP53 1971/4885CYP3A4 1738/4885MAP4K4 4128/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR TP53 1971/4885CYP3A4 1738/4885MAP4K4 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.